We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Feedback Plc | LSE:FDBK | London | Ordinary Share | GB00BJN59X09 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 97.50 | 95.00 | 100.00 | 97.50 | 97.50 | 97.50 | 5,188 | 07:36:53 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Electronic Computers | 1.03M | -2.92M | -0.2188 | -4.46 | 13M |
Date | Subject | Author | Discuss |
---|---|---|---|
14/2/2022 17:09 | LR2, I am well aware of the new financial year and I hope you are right and Bleepa does see some money thrown towards them. I suppose one could look at that figure of 900 clinicians at Pennine who are now using Bleepa and view that as a huge positive and I do believe it is. Hat still waiting if we never see a contract coming through from them. If the first CDC contract ever comes through, I will be doubling my multi million holding, so yes buyers are likely waiting for something like this first. | petekand | |
14/2/2022 15:10 | Pete, the Pennine Acute Hospital Trust signed up for Bleepa rollout in April 2020 and the Royal Berkshire Foundation Trust in late March 2021. Why then? Why springtime? Because each and every NHS hospital has the same new financial year start date of April. In April of each year all NHS hospitals get their hands on a new cash lump sum to spend. So, that's why I believe there will plenty of news in March / April. News about hospitals, community diagnostic centres (9), and India of course. If there isn't any NHS news in the next two months, then Bleepa has a problem with the NHS and will have to double down on its Indian leads of Orissa and Rajasthan. Incidentally, both states have roughly similar populations to the UK (Orissa - 47 million, Rajasthan - 83 million, UK - 68 million). If Bleepa fails to take off in the UK NHS this financial year then India must pick up the slack. We have an Indian partner in QURE.AI and the Orissa pilot has 'recently (been) deployed at a pilot hospital' so I'm not unduly concerned about India. As for the lack of trades recently, surely that shows we just have very few soft sellers about in the market place, and few buyers also as I suspect that they are awaiting news of signed contracts to limit buying risk. They appear to want financial security at the risk of paying a higher share price after contracts news breaks. | lr2 | |
14/2/2022 14:09 | The frustrating thing here is that it would only take a couple of CDC contracts to put Feedback into a very serious potential growth category. The risk I’m worried about is that they don’t sell the basic system first as a starter and end up with lots of “extras” requested that need development. That would be time for TO to put on a commercial hat. If the NHS are serious, put some money on the table and enter a development contract on top of the base system contract. If a customer likes something, their bluff has to be called early on. “Buy this now and use it to help and we’ll upgrade add-ons”. | yump | |
14/2/2022 14:02 | Why don’t you just stay in your conspiracy echo chamber and stick to FDBK. | yump | |
14/2/2022 13:21 | Who was that poster who only takes his cue from the idiot Dr John Campbell when it comes to all matters relating to the jabs? Well, the idiot now is suggesting the risk of developing myocarditis is some 133 greater in those who volunteered to take part in the great experiment. The same Campbell who was urging his 2mill plus subscribers to roll up their sleeves without a second thought despite alarming data suggesting otherwise. | petekand | |
14/2/2022 13:12 | In all honesty you do suggest this every year and so you may be right one year. Looking at the non-action in the trades column, I suspect the market does not seem to agree. I note from results that Bleepa is now in the hands of circa 900 clinicians at Pennine. Feedback may as well change its status to that of a registered charity. As far as the latest interview is concerned, Tom sounds a little uncertain in my opinion, banging on about the AWS grant and at the same time stating we need Indian partners to begin the pilot. There is absolutely nothing new except the same waffle he has been repeating for the last two years. | petekand | |
14/2/2022 07:24 | My thought too. | ducatiman | |
14/2/2022 06:51 | I suspect we'll have lots of news in March and April. | lr2 | |
14/2/2022 05:02 | Cheers LR2. Not long now, hopefully. | ducatiman | |
13/2/2022 20:55 | Courtesy of Investor Bill over on the other place. | lr2 | |
12/2/2022 16:32 | Busy week indeed Ged. Yep, next few months will tell. Plenty of irons in plenty of fires! | ducatiman | |
12/2/2022 09:45 | Ducatiman thanks. Post 9622, also in the header. Busy week? Indeed Yump. It's going to be an interesting couple of months. Make or break time? | ged5 | |
12/2/2022 09:37 | 9 CDC’s should yield something and give a clue to the future. At least that number is specific. | yump | |
12/2/2022 08:25 | I don’t think this has been posted. Apologies if it has. | ducatiman | |
10/2/2022 22:21 | "MPD also provides expertise and guidance in introducing new technologies and applications such as Bleepa to facilitate the safe capture and sharing of images taken by clinical staff, including establishing protocols for patient consent, etc." ____________________ Full steam ahead at the Royal Berkshire NHS Foundation Trust then. | lr2 | |
10/2/2022 16:40 | Just going to mention that. I don't recall that being in the RNS. Also page 23 breaks down the target markets. | ged5 | |
10/2/2022 16:30 | We are currently in discussion with ~9 CDCs | ragnarr | |
10/2/2022 16:13 | 1bond I'm afraid what gets to me is that 3 of us made roughly that in the first year from an very early website until Google trashed it. That was literally from a bedroom (well 3 bedrooms). Should have floated it. | yump | |
10/2/2022 16:03 | Interim results presentationfor the 6 months ended 30 November 202110 February 2022https://fbkmed.c | ragnarr | |
10/2/2022 14:19 | Its never good when a company has to resort to desperate sensational highlights to try and boost the share price and treat shareholders like fools. For example, Significant increase in revenues - reflecting initial Bleepa sales and highlighting strength of the Company's refocused business model. Revenues were up a minuscule 9% to £179k. Whats the costs base, When are you going to sign a meaningful contract delivering real revenues? You have raised over £15m in the last two years and delivered zero!!!! Promises, promises, promises | 1bond | |
10/2/2022 12:25 | Photon ;-)) Perhaps we still have the known unknowns and all that to come... I just hope they don’t go crazy with spending before the first couple of decent contracts that demonstrate viability and scalability. | yump |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions